Expert Interview
Discussing therapies for BCG unresponsive NMIBC with a focus on detalimogene voraplasmid
Ticker(s): ENGNInstitution: One Urology
- Urologist at One Urology in California.
- Currently manages 125-200 patients with bladder cancer.
- Clinical focus on urologic cancer, stone disease, incontinence, erectile dysfunction, men’s health, and infertility.
What are the current challenges in treating BCG-unresponsive NMIBC patients, specifically in managing disease recurrence and progression with intravesical therapies?
Added By: slingshot_insightsHow does the availability and shortage of agents like BCG and mitomycin influence treatment protocols, and what alternatives are viable during shortages?
What are the clinical barriers to adopting newer therapies (e.g., Keytruda, Adstiladrin) in terms of cost, availability, patient compliance, and practical ease of administration?
Added By: slingshot_insightsHow does the revision in the LEGEND trial protocol regarding Ta disease resection impact the study’s integrity, and what are potential implications for patient outcomes?
Added By: slingshot_insightsWhat role do practical considerations, like ease of administration and patient discomfort, play in the decision to choose between therapies assuming similar efficacy?
Added By: slingshot_insightsAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
